Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

January 14, 2003 14 January, 2003

Pheromone Sciences Appoints Jim Wooder to Board of Directors

Toronto, Ontario (January 14, 2003) - Pheromone Sciences Corp (TSX-V:PHS), is pleased to announce the appointment of Mr. Jim Wooder, well-known and respected Toronto businessman, to its Board of Directors.

Mr. Wooder brings a wealth of investment knowledge and business acumen to the Pheromone Sciences' Board of Directors. He is currently Vice President of Helix Investments (Canada) Inc., a North American- based venture capital company with assets of $200 million. Mr. Wooder has held this position since 1993. Prior to this Mr.Wooder spent several years in the Canadian Banking Industry. In addition, Mr. Wooder has held senior management positions with prominent investment and venture capital firms.

Having participated at the Board of Director level in some 50 companies, Mr Wooder is Chairman of The Hanen Centre, an internationally renowned charity that develops programs to assist teachers and parents in the teaching of children with speech problems.

"We are extremely pleased that Mr. Wooder has accepted this appointment to our Board. His experience and proven abilities as a manager and investor will be of benefit to us as we enter this crucial phase in our development and growth ", commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp.

The appointment, which is subject to regulatory approval, is part of an ongoing program to enhance the independent nature of the Board.

In addition, Mr. Douglas Marett's duties as Chief Scientific Officer are now being carried out on a consulting basis.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Pheromone Sciences Corp is a member of MEDEC, which is the national industry association representing over 120 medical device and diagnostic companies. Member companies are dedicated to serving the health care community through the provision of high quality medical products and services that benefit Canadians.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.